doi : 10.1016/S1936-8798(23)00640-4
Volume 16, Issue 8, 24 April 2023, Pages A1-A4
doi : 10.1016/S1936-8798(23)00706-9
Volume 16, Issue 8, 24 April 2023, Pages A5-A13
Mackram F. Eleid, MD, a Jeremy D. Collins, MD, b Paul Mahoney, MD, c Eric E. Williamson, MD,b Ammar M. Killu, MBBS,a Brian K. Whisenant, MD, d Charanjit S. Rihal, MD, MBA, a Mayra E. Guerrero, MD
doi : 10.1016/j.jcin.2023.01.357
Volume 16, Issue 8, 24 April 2023, Pages 885-895
An increasing number of patients with mitral valve disease are high risk for surgery and in need of less invasive treatments including transcatheter mitral valve replacement (TMVR). Left ventricular outflow tract (LVOT) obstruction is a predictor of poor outcome after TMVR, and its risk can be accurately predicted using cardiac computed tomography analysis.
Marianna Adamo, MD,a, * Daniela Tomasoni, MD,a, * Lukas Stolz, MD,b Thomas J. Stocker, MD,b Edoardo Pancaldi, MD, a Benedikt Koell, MD, c Nicole Karam, MD,d Christian Besler, MD, e Cristina Giannini, MD, f Francisco Sampaio, MD,g Fabien Praz, MD,h Tobias Ruf, MD,i Louis Pechmajou, MD, d Michael Neuss, MD, j Christos Iliadis, MD,k Stephan Baldus, MD,k Christian Butter, MD, j Daniel Kalbacher, MD, c Philipp Lurz, MD,e Bruno Melica, MD,g Anna S. Petronio, MD, f Ralph Stephan von Bardeleben, MD,i Stephan Windecker, MD,h Javed Butler, MD,l Gregg C. Fonarow, MD,m Jörg Hausleiter, MD, b,y Marco Metra, MD
doi : 10.1016/j.jcin.2023.01.362
Volume 16, Issue 8, 24 April 2023, Pages 896-905
Guideline-directed medical therapy (GDMT) optimization is mandatory before transcatheter edge-to-edge mitral valve repair (M-TEER) in patients with secondary mitral regurgitation (SMR) and heart failure (HF) with reduced ejection fraction (HFrEF). However, the effect of M-TEER on GDMT is unknown.
David W.M. Muller, MBBS, MD
doi : 10.1016/j.jcin.2023.02.023
Volume 16, Issue 8, 24 April 2023, Pages 906-908
Vera Fortmeier, MD,a, * Mark Lachmann, MD,b,c, * Maria I. Körber, MD,d Matthias Unterhuber, MD, e Anne R. Schöber, MD, e Lukas Stolz, MD, f Thomas J. Stocker, MD, c,f Mohammad Kassar, MD, g Muhammed Gerçek, MD, a Tanja K. Rudolph, MD,a Fabien Praz, MD,g Stephan Windecker, MD,g Roman Pfister, MD, d Stephan Baldus, MD, d Karl-Ludwig Laugwitz, MD, b,c Jörg Hausleiter, MD, c,f Philipp Lurz, MD, e Volker Rudolph, MD
doi : 10.1016/j.jcin.2023.01.378
Volume 16, Issue 8, 24 April 2023, Pages 909-923
Men and women differ regarding comorbidities, pathophysiology, and the progression of valvular heart diseases.
Georg Nickenig, MD, Atsushi Sugiura, MD, PHD
doi : 10.1016/j.jcin.2023.02.035
Volume 16, Issue 8, 24 April 2023, Pages 924-926
Gilbert H.L. Tang, MD, MS C, MBA, a, * Syed Zaid, MD, b, * Neal S. Kleiman, MD, b Sachin S. Goel, MD,b Shinichi Fukuhara, MD, c Mateo Marin-Cuartas, MD,d Philipp Kiefer, MD, d Mohamed Abdel-Wahab, MD,d Ole De Backer, MD, e Lars Søndergaard, MD,e Shekhar Saha, MD, f Christian Hagl, MD,g Moritz Wyler von Ballmoos, MD, PH D, MPH,b Oliver Bhadra, MD, h Lenard Conradi, MD,h Kendra J. Grubb, MD, MHA,
doi : 10.1016/j.jcin.2023.01.376
Volume 16, Issue 8, 24 April 2023, Pages 927-941
Valve reintervention after transcatheter aortic valve replacement (TAVR) failure has not been studied in detail.
Robert B. Hawkins, MD, MSC ,a,b G. Michael Deeb, MD,a,b Devraj Sukul, MD, MS C,a,b Himanshu J. Patel, MD, a,b Sarah K. Gualano, MD,a,b Stanley J. Chetcuti, MD,a,b P. Michael Grossman, MD, a,b Gorav Ailawadi, MD, MBA, a,b Shinichi Fukuhara, MD
doi : 10.1016/j.jcin.2023.03.015
Volume 16, Issue 8, 24 April 2023, Pages 942-953
Aortic stenosis treatment should consider risks and benefits for lifetime management. Although the feasibility of redo transcatheter aortic valve replacement (TAVR) remains unclear, concerns are emerging regarding reoperation after TAVR.
Giuseppe Tarantini, MD, PHD, Tommaso Fabris, MD
doi : 10.1016/j.jcin.2023.03.014
Volume 16, Issue 8, 24 April 2023, Pages 954-957
Sripal Bangalore, MD, MHA, a James M. Horowitz, MD, b Daren Beam, MD, c Wissam A. Jaber, MD, d Sameer Khandhar, MD, e Catalin Toma, MD, f Mitchell D. Weinberg, MD, MBA, g Bushra Mina, MD h
doi : 10.1016/j.jcin.2023.02.004
Volume 16, Issue 8, 24 April 2023, Pages 958-972
Patients with acute pulmonary embolism (PE) and hypotension (high-risk PE) have high mortality. Cardiogenic shock can also occur in nonhypotensive or normotensive patients (intermediate-risk PE) but is less well characterized.
Geoffrey D. Barnes, MD, MSC ,a Amber Liles, MD
doi : 10.1016/j.jcin.2023.03.017
Volume 16, Issue 8, 24 April 2023, Pages 973-975
Nishant Jain, MD,a Muhammad A. Sheikh, MD,b Divyansh Bajaj, MD,c Whitney Townsend, BA, d Richard Krasuski, MD,e Eric Secemsky, MD, f Saurav Chatterjee, MD,g Victor Moles, MD, h Prachi P. Agarwal, MD, MS, i Jonathan Haft, MD, j Scott H. Visovatti, MD, k Thomas M. Cascino, MD, MS C,h Kenneth Rosenfield, MD,l Brahmajee K. Nallamothu, MD, h,m Vallerie V. Mclaughlin, MD,h Vikas Aggarwal, MD, MPH
doi : 10.1016/j.jcin.2023.01.361
Volume 16, Issue 8, 24 April 2023, Pages 976-983
Ehtisham Mahmud, MD, Lawrence Ang, MD
doi : 10.1016/j.jcin.2023.02.017
Volume 16, Issue 8, 24 April 2023, Pages 984-985
Ryosuke Ito, MD, PH D, Jun Yamashita, MD, PHD, Yuki Nakajima, MD, Taishiro Chikamori, MD, PH D
doi : 10.1016/j.jcin.2022.12.013
Volume 16, Issue 8, 24 April 2023, Pages 986-987
Pradyumna Agasthi, MD,a Frank Cetta, MD,a,b Jason H. Anderson, MD a,b
doi : 10.1016/j.jcin.2023.01.021
Volume 16, Issue 8, 24 April 2023, Pages 988-990
Efstratios I. Charitos, MD, P HD, a,b Nikolai Busch, MD, b Matthias Renker, MD, b Oliver J. Liakopoulos, MD, PHD, a Ulrich Fischer-Rasokat, MD, PHD, b Andrea Colli, MD, PHD, c Christian W. Hamm, MD, P HD, b,d Yeong-Hoon Choi, MD, PH D, a Won-Keun Kim, MD, PHD
doi : 10.1016/j.jcin.2022.12.014
Volume 16, Issue 8, 24 April 2023, Pages 991-992
Fei Chen, MD,a, * Hong Qian, MD, b, * Zhengang Zhao, MD,a Xin Wei, MD, a Xi Li, MD, a Yuan Feng, MD, a Wei Meng, MD,b Mao Chen, MD, P HD
doi : 10.1016/j.jcin.2023.01.009
Volume 16, Issue 8, 24 April 2023, Pages 993-996
Takeshi Nishi, MD, PHD, Teruyoshi Kume, MD, P HD, Ryotaro Yamada, MD, P HD, Yoji Neishi, MD, PHD, Shiro Uemura, MD, PHD
doi : 10.1016/j.jcin.2023.01.370
Volume 16, Issue 8, 24 April 2023, Pages 997-999
Alfredo MatÃas Rodriguez-Granillo, MD Carolina Salvatori, MD Fabricio Gastón Procopio, MD Giuseppe Biondi-Zoccai, MD, MStat on behalf of the Counsil of Clinical and Therapeutical Cardiology from de Argentinian Society of Cardiology (SAC)
doi : 10.1016/j.jcin.2023.02.032
Volume 16, Issue 8, 24 April 2023, Page 1000
Derrick Y. Tam, MD, PhD Rodolfo V. Rocha, MD, PhD Stephen E. Fremes, MD, MSc *Douglas S. Lee, MD, PhD
doi : 10.1016/j.jcin.2023.03.031
Volume 16, Issue 8, 24 April 2023, Page 1001
Shigetaka Kageyama, MD Yoshinobu Onuma, MD Scot Garg, MD *Patrick W. Serruys, MD
doi : 10.1016/j.jcin.2023.02.024
Volume 16, Issue 8, 24 April 2023, Pages 1002-1003
Christopher P. Kovach, MD, MSc Javier A. Valle, MD, MSCS *Stephen W. Waldo, MD
doi : 10.1016/j.jcin.2023.03.006
Volume 16, Issue 8, 24 April 2023, Page 1004
Agam Bansal, MD Mohammed Faisaluddin, MD Siddharth Agarwal, MD Osamah Badwan, MD Serge C. Harb, MD Amar Krishnaswamy, MD Marc Gillinov, MD *Samir R. Kapadia, MD
doi : 10.1016/j.jcin.2023.01.355
Volume 16, Issue 8, 24 April 2023, Pages 1005-1007
Alejandra Chavez Ponce, MD* Sahar Samimi, MD* Ahmed El Shaer, MBBS Samian Sulaiman, MD Mackram F. Eleid, MD Mayra Guererro, MD Jeremy Thaden, MD Charanjit S. Rihal, MD yMohamad Alkhouli, MD
doi : 10.1016/j.jcin.2023.01.379
Volume 16, Issue 8, 24 April 2023, Pages 1008-1009
doi : 10.1016/S1936-8798(23)00704-5
Volume 16, Issue 8, 24 April 2023, Pages I-CXXXVIII
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟